STABILITY OF SOLUTIONS OF 2,3-DIPHENYLCYCLOPROPENONE IN VARIOUS SOLVENTS. A NOVEL FORMULA - DIPHENYLCYCLOPROPENONE IN ISOPROPANOL MAY BE USEFUL IN TOPICAL THERAPY OF PATIENTS WITH ALOPECIA AREATA.

The aim of this study was to evaluate the chemical stability of diphenylcyclopropenone (DCP) in var- ious solvents. DCP is being used in topical therapy in patients with alopecia areata (AA). The solvents for DCP used so far were acetone, ethanol and propylene glycol.

STUDIES ON STABILITY OF 2,3-DIPHENYLCYCLOPROPENONE IN CONTACT WITH WATER AND AQUEOUS NaCI SOLUTIONS. CONCLUSIONS FOR PURPOSE OF TOPICAL THERAPY OF PATIENTS WITH ALOPECIA AREATA.

Diphenylcyclopropenone (DCP) is a topically administered agent used for more than three decades for treatment of alopecia areata (AA). Moreover, numerous recent studies show it's efficiency in treatment of cutaneous metastatic melanoma. Despite being a potentially useful drug still very little is known about the pharmacokinetics of DCP.

Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: An observational study of nonresponder patients with alopecia areata.

The topical contact sensitiser diphenylcyclopropenone (DCP) remains one of the most effective treatment modalities for alopecia areata (AA). However, some patients (nonresponders) do not respond to this treatment because they do not have an allergic reaction to DCP. The aim of this study was to investigate the potential role of imiquimod in inducing an allergic reaction to DCP in nonresponders.

Changes in distribution pattern of CD8 lymphocytes in the scalp in alopecia areata during treatment with diphencyprone.

For many years, the role of T lymphocytes was hypothesized as being a major factor responsible for hair loss in alopecia areata (a.a.).